Disease recurrence at 12 months – total (AFS score) · women having endometriosis surgery
1 finding from 1 review
Hirsutism ‐ Clinical F‐G score · aAdult women with PCOS
1 finding from 1 review
Adverse events ‐ Severe · aAdult women with PCOS
Oral contraceptive pill (OCP) may leads to lower adverse events ‐ Severe compared with metformin combined with OCP (low certainty).
1 finding from 1 review
Minor adverse events · aAdult women with PCOS
Oral contraceptive pill (OCP) may leads to lower adverse events ‐ Minor compared with metformin combined with OCP (low certainty).
1 finding from 1 review
Improved menstrual pattern · aAdult women with PCOS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acne ‐ Clinical acne score · aAdult women with PCOS
1 finding from 1 review
Body‐mass index (BMI) · aAdult women with PCOS
1 finding from 1 review
Hirsutism ‐ Clinical F‐G score · adolescent women with PCOS
1 finding from 1 review
Adverse events ‐ Severe · adolescent women with PCOS
It is very uncertain whether oral contraceptive pill (OCP) changes adverse events ‐ Severe compared with metformin combined with OCP (very low certainty).
1 finding from 1 review
Minor adverse events · adolescent women with PCOS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improved menstrual pattern · adolescent women with PCOS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acne ‐ Visual analogue scale or Clinical acne score · adolescent women with PCOS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Body‐mass index (BMI) · adolescent women with PCOS
1 finding from 1 review
Death during study period · people with liver metastases
It is very uncertain whether transarterial embolisation and transarterial chemoembolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
1 finding from 1 review
Tumour response measures · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and complications · people with liver metastases
1 finding from 1 review
Death during study period · people with liver metastases
It is very uncertain whether transarterial chemoembolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
1 finding from 1 review
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis · people with liver metastases
1 finding from 1 review
Tumour response measures · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found